Free Trial
→ Inside the Options Play With a High Historical Win Rate (From TradeWins) (Ad)tc pixel
NASDAQ:NVNO

enVVeno Medical Earnings Date & Estimates

enVVeno Medical logo
$8.75 +0.57 (+6.97%)
Closing price 10/9/2026 03:59 PM Eastern
Extended Trading
$8.60 -0.15 (-1.71%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

enVVeno Medical is expected to report earnings on Friday, October 30, 2026, before market opens.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from enVVeno Medical

enVVeno Medical is expected to post earnings of -$3.27 per share on revenue of $2.25 million. In the same quarter a year earlier enVVeno Medical reported -$8.05 per share. enVVeno Medical last reported on July 30, 2026, posting -$5.37 per share and missing the -$4.69 consensus estimate. enVVeno Medical has beaten the consensus EPS estimate in 2 of its last 5 quarters.

Consensus Estimates

Consensus EPS
-$3.27
Expected Revenue
$2.25 million
Prior-Year EPS
-$8.05

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$5.37 (Missed by -$0.68)
EPS Beat Rate
2 of last 5 quarters

Prepare for the Earnings Call

enVVeno Medical Earnings FAQ

enVVeno Medical (NASDAQ:NVNO) is estimated to report earnings on Friday, October 30, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect enVVeno Medical to post earnings of -$3.27 per share for the quarter.

The consensus revenue estimate for enVVeno Medical is $2.25 million for the quarter.

enVVeno Medical Earnings Headlines

enVVeno Medical Corporation: enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial
October 2, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-10/69742489-envveno-medical-corporation-envveno-medical-s-first-in-class-envve-system-to-be-featured-at-the-veins-2026-innovation-summit-as-company-advances-towa-200.htm
enVVeno Medical Corporation: enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series
September 16, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69596541-envveno-medical-corporation-envveno-medical-ceo-rob-berman-goes-direct-to-investors-with-new-wtf-video-series-200.htm
Inside the Options Play With a High Historical Win Rate
Ian Cooper's newest strategy targets triple-digit returns in just 9 days. It doesn't work every time, but a 73% win rate and 2,671% return on capital stand on their own. Ian is breaking down the full strategy and offering his newest report at no charge.tc pixel
October 10 at 1:00 AM  |  TradeWins (Ad)
enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series
September 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/envveno-medical-ceo-rob-berman-125000759.html
enVVeno Medical Corporation: enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand
September 11, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69555738-envveno-medical-corporation-envveno-medical-presentation-from-h-c-wainwright-conference-now-available-on-demand-200.htm
enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference
August 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/envveno-medical-participates-virtual-investor-130100642.html
See More enVVeno Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like enVVeno Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enVVeno Medical and other key companies, straight to your email.

About enVVeno Medical

enVVeno Medical (NASDAQ:NVNO) (NASDAQ: NVNO) is a medical device company focused on developing bioprosthetic solutions for vascular and cardiovascular diseases. The company’s technologies are designed to address conditions for which existing medical and surgical treatments may be limited or ineffective.

Its lead product candidate is the VenoValve, an investigational surgically implanted tissue-based valve intended to treat chronic deep venous insufficiency, including symptoms associated with post-thrombotic syndrome. The device is designed to help restore one-way blood flow in the deep veins of the leg and reduce venous hypertension. VenoValve has been evaluated in clinical studies and remains subject to regulatory review.

enVVeno also has pursued transcatheter heart-valve technologies, including the enVVe system, which is intended to treat certain forms of tricuspid regurgitation. The company was formerly known as Hancock Jaffe Laboratories and adopted the enVVeno Medical name in 2021. It is headquartered in Nashville, Tennessee, and its products are in development and regulatory stages rather than broadly marketed commercial products.

View enVVeno Medical Profile
Earnings Tools